Farnesyltransferase Inhibitors for Lamin A Protein Defects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hutchinson-Gilford Progeria Syndrome (HGPS) and other laminopathies are characterized by aberrant lamin A protein due to a mutation that prevents proper farnesylation and cleavage, leading to abnormal cellular function and premature aging, for which current treatments lack effective solutions.
Innovation Solution
The use of farnesyltransferase inhibitors (FTIs) to prevent farnesylation of the aberrant lamin A protein, thereby reducing its abnormal function and increasing the levels of prelamin A, which can improve disease status by addressing the root cause of cellular defects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If farnesyltransferase inhibitors are used to prevent farnesylation of aberrant lamin A protein, then abnormal cellular function is reduced and nuclear morphology improves, but the complexity of treatment increases and current effective solutions are lacking
Solution Approach 1:
Farnesyltransferase inhibitors act as intermediary compounds that block the farnesyltransferase enzyme, preventing the aberrant farnesylation of lamin A protein. This intermediary approach targets the specific biochemical defect without requiring complex genetic interventions, thereby improving cellular function while maintaining relatively simple treatment administration
Solution Approach 2:
The treatment changes the biochemical parameter of farnesylation status by inhibiting the farnesyltransferase enzyme. This parameter change prevents the formation of aberrantly farnesylated lamin A protein, leading to improved nuclear morphology and cellular function without requiring complex multi-step procedures
2Quantity of substance
If FTIs prevent farnesylation of lamin A protein, then prelamin A levels increase and disease status improves, but the mutation preventing proper farnesylation and cleavage remains untreated
Solution Approach 1:
Farnesyltransferase inhibitors apply preliminary anti-action by blocking the farnesylation step before the aberrant lamin A protein can be formed. This prevents the harmful post-translational modification that leads to protein misfolding and nuclear envelope disruption, thereby increasing prelamin A levels and improving disease status
3Duration of action of stationary object
If current treatments are used for HGPS and laminopathies, then disease progression is managed, but effective solutions are lacking and underlying protein defects are not addressed
Solution Approach 1:
The treatment converts the harmful constitutive farnesylation of aberrant lamin A into a beneficial effect by using farnesyltransferase inhibitors to block this abnormal modification. This converts the pathological process into a therapeutic opportunity, improving treatment effectiveness by directly addressing the underlying protein defect rather than merely managing symptoms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
FTIs effectively reduce the aberrant lamin A protein levels, improving nuclear morphology and cellular function, offering a potential therapeutic option for HGPS and other laminopathies by targeting the underlying protein defect.
Implementation Method 1
The CAAX box signals for isoprenylation, the addition of a 15-carbon farnesyl isoprenoid lipid group to the cysteine by the enzyme farnesyltransferase
Data Source
AI summary
Although it can be farnesylated, the mutant lamin A protein expressed in Hutchison Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors.